We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

MEDIX BIOCHEMICA AB

Develops, produces and markets monoclonal antibodies, antibody services and recombinant antigens for IVD industry, as... read more Featured Products: More products

Download Mobile App




Medix Biochemica Acquires German Immunoassay Solutions Developer Candor Bioscience

By LabMedica International staff writers
Posted on 23 Jan 2025
Print article
Image: CANDOR Bioscience GmbH has joined the worldwide Medix Biochemica Group through an acquisition (Photo courtesy of Medix Biochemica)
Image: CANDOR Bioscience GmbH has joined the worldwide Medix Biochemica Group through an acquisition (Photo courtesy of Medix Biochemica)

Medix Biochemica (Espoo, Finland), a global leader in the supply of critical raw materials for the in vitro diagnostics (IVD) industry, has acquired CANDOR Bioscience GmbH (Allgäu, Germany), a developer and manufacturer of premium immunoassay solutions.

Medix Biochemica is a market-leading, independent supplier of critical raw materials to the IVD industry worldwide. The company develops, produces, and supplies high-quality antibodies, antigens, and other critical IVD raw material products to IVD companies worldwide, enabling the delivery of accurate IVD tests to billions of patients. CANDOR Bioscience is a provider of a comprehensive selection of premium solutions for immunoassays, including HAMA and interference blockers, surface blockers, stabilizers, and buffer solutions. By using CANDOR Bioscience’s solutions, immunoassay manufacturers can improve reliability of test results, simplify assay designs and reduce process times. The acquisition of CANDOR Bioscience both strengthens Medix Biochemica’s range of high-quality raw materials to the worldwide IVD industry and enhances its capabilities to support test manufacturers in immunoassay development.

“We are delighted to welcome CANDOR into the Medix Biochemica family,” said Steve Ferguson, CEO of Medix Biochemica. “The partnership with CANDOR strengthens Medix Biochemica’s ability to support our customer base by adding complementary expertise in immunoassay development and broadening our offering of critical IVD raw materials with a leading portfolio of premium blockers and stabilizers. Together, we will continue to provide the highest quality raw materials that enable diagnostic innovation, and we look forward to a successful collaboration with the CANDOR team.”

“Joining forces with Medix Biochemica is an exciting milestone for CANDOR,” added Dr. Tobias Polifke and Dr. Peter Rauch, co-founders and Managing Directors of CANDOR Bioscience. “We are proud of our legacy in providing differentiated, high-performance solutions for immunoassay development, and we share Medix Biochemica’s commitment to quality and innovation. By combining our capabilities and offerings, we will be better positioned to support the evolving needs of our customers. Medix Biochemica’s products, including antibodies and quality control materials, perfectly complement our solutions, enhancing the value we offer to partners in the IVD industry.”

Related Links:
Medix Biochemica
CANDOR Bioscience GmbH

Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Immunofluorescence Analyzer
MPQuanti
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Pathology

view channel
Image: The study examined the influence of pre-analytical conditions on cell-free microRNA stability in blood plasma samples (Photo courtesy of 123RF)

Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples

Scientists worldwide are working to enhance the quality of diagnostics and prognosis for various diseases, including cancer, by analyzing different body fluids such as blood, urine, and saliva.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.